A Bioequivalence Study of 2.5-mg Saxagliptin/5-mg Dapagliflozin and 5-mg Saxagliptin/10-mg Dapagliflozin Fixed Dose Combination Tablets Relative to Coadministration of Their Respective Individual Components in Healthy Subjects and a Characterization of the Effect of Food on the Fixed Dose Combination Tablets
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Dapagliflozin/saxagliptin (Primary) ; Dapagliflozin; Saxagliptin
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Primary endpoint has been met. (Area under the drug concentration-time curve)
- 09 Jun 2015 Primary endpoint has been met. (Peak drug concentration)